Rate increased by 17.0 percent per month before March 2020; increased 63.5 percent faster from March 2020 onward
SSRIs Linked to Reduced Relative Risk for Mortality in COVID-19
Relative risks for mortality significantly reduced for any SSRI, fluoxetine, and fluoxetine or fluvoxamine
Fluvoxamine Cuts Hospitalizations in High-Risk COVID-19 Outpatients
Rate of high-risk COVID-19 outpatients needing prolonged emergency care or transfer to tertiary hospital lower with fluvoxamine versus placebo